Regencell Bioscience Holdings Limited (RGC)
NASDAQ
7.67
-2.14 (-21.81%)
Closed
Oct 23, 2026
Day's Range
7.559.82
52 wk Range
4.5169.00
Financial Statements - RGC - Regencell Bioscience Holdings Limited
Revenue
0
Net Income
-4.36M▲ 28.0%
EBITDA
-3.99M▲ 27.5%
Free Cash Flow
-4.00M▲ 19.7%
Income Statement
| Period Ending | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|---|
| Sales | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | - | -4.73M | -6.27M | -7.61M | -1.38M | -812.37K |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | 373.50K | 211.34K | 23.21K | 34.61K | - |
| Pre Tax Income | - | -4.36M | -6.06M | -7.59M | -1.34M | -812.37K |
| Income Tax | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | -4.36M | -6.06M | -7.59M | -1.34M | -812.37K |
| EPS Basic | -0.0072 | -0.0087 | -0.0119 | -0.015263 | -0.106529 | -0.064259 |
| EPS Diluted | -0.0072 | -0.0087 | -0.0119 | -0.015263 | -0.106529 | -0.064259 |
| Basic Shares Outstanding | 494.48M | 494.48M | 494.48M | 486.61M | 12.64M | 12.64M |
| Diluted Shares Outstanding | 494.48M | 494.48M | 494.48M | 486.61M | 12.64M | 12.64M |
| Ebit | - | -4.73M | -6.27M | -7.61M | -1.38M | -812.37K |
| Ebitda | - | -3.99M | -5.50M | -7.01M | -1.35M | -802.85K |
| Net Income Continuous Operations | - | -4.36M | -6.06M | -7.59M | -1.34M | -812.37K |
| Minority Interests | - | 61.38K | 191.19K | 148.61K | 0 | 0 |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
